Concurrent renal cell carcinoma and hematologic malignancies: Nine case reports.
Case report
Hematologic malignancy
Immune system
Immunotherapy
Lymphoma
Oncology
Renal cell cancer
Journal
World journal of clinical oncology
ISSN: 2218-4333
Titre abrégé: World J Clin Oncol
Pays: United States
ID NLM: 101549149
Informations de publication
Date de publication:
24 Aug 2020
24 Aug 2020
Historique:
received:
17
01
2020
revised:
21
05
2020
accepted:
27
06
2020
entrez:
4
9
2020
pubmed:
4
9
2020
medline:
4
9
2020
Statut:
ppublish
Résumé
The presence of renal cell carcinoma (RCC) and hematologic malignancies (HM) in the same patient is rarely observed. Three primary findings have been described in these patients, including male gender and lymphoid malignancy predominance, and the HM are usually diagnosed before or simultaneously with the RCC. There is a lack of evidence about clinical outcomes in this setting. We report the common characteristics of 9 patients diagnosed with concurrent RCC and HM and their clinical course and response to treatment. Four (44%) patients were diagnosed with RCC prior to the HM, the diagnosis was simultaneous in 4 (44%) patients, and 1 (11%) patient was diagnosed with the HM prior to the RCC. No patients were treated with cytotoxic chemotherapy or radiation between the diagnosis of RCC and HM. Several unique features were seen in our case series, such as 3 simultaneous cancers in 1 (11%) patient, a splenectomy leading to remission of diffuse large B cell lymphoma without the use of chemotherapy in 1 (11%) patient, chemotherapy and rituximab for lymphoma resulting in a complete response in primary RCC in 1 (11%) patient, and immunotherapy providing an excellent response for primary renal leiomyosarcoma in 1 (11%) patient. These findings highlight the potential role of immune system dysregulation in patients with the diagnosis of RCC and HM whereby the first malignancy predisposes to the second through an immunomodulatory effect. HM have the potential of being confused with lymph node metastasis from kidney cancer. Lymph node biopsy may be necessary at the time of initial diagnosis or in cases of mixed response to therapy. Long-term medical surveillance is warranted when a patient is diagnosed with RCC or HM. Clinicians should be aware of the higher prevalence of male gender and lymphoid malignancy with concurrent RCC and HM and that either of these conditions may be diagnosed first or they may be diagnosed simultaneously.
Sections du résumé
BACKGROUND
BACKGROUND
The presence of renal cell carcinoma (RCC) and hematologic malignancies (HM) in the same patient is rarely observed. Three primary findings have been described in these patients, including male gender and lymphoid malignancy predominance, and the HM are usually diagnosed before or simultaneously with the RCC. There is a lack of evidence about clinical outcomes in this setting. We report the common characteristics of 9 patients diagnosed with concurrent RCC and HM and their clinical course and response to treatment.
CASE SUMMARY
METHODS
Four (44%) patients were diagnosed with RCC prior to the HM, the diagnosis was simultaneous in 4 (44%) patients, and 1 (11%) patient was diagnosed with the HM prior to the RCC. No patients were treated with cytotoxic chemotherapy or radiation between the diagnosis of RCC and HM. Several unique features were seen in our case series, such as 3 simultaneous cancers in 1 (11%) patient, a splenectomy leading to remission of diffuse large B cell lymphoma without the use of chemotherapy in 1 (11%) patient, chemotherapy and rituximab for lymphoma resulting in a complete response in primary RCC in 1 (11%) patient, and immunotherapy providing an excellent response for primary renal leiomyosarcoma in 1 (11%) patient.
CONCLUSION
CONCLUSIONS
These findings highlight the potential role of immune system dysregulation in patients with the diagnosis of RCC and HM whereby the first malignancy predisposes to the second through an immunomodulatory effect. HM have the potential of being confused with lymph node metastasis from kidney cancer. Lymph node biopsy may be necessary at the time of initial diagnosis or in cases of mixed response to therapy. Long-term medical surveillance is warranted when a patient is diagnosed with RCC or HM. Clinicians should be aware of the higher prevalence of male gender and lymphoid malignancy with concurrent RCC and HM and that either of these conditions may be diagnosed first or they may be diagnosed simultaneously.
Identifiants
pubmed: 32879850
doi: 10.5306/wjco.v11.i8.644
pmc: PMC7443826
doi:
Types de publication
Case Reports
Langues
eng
Pagination
644-654Informations de copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Références
Am J Surg Pathol. 2010 Feb;34(2):238-42
pubmed: 20090506
Am J Hematol. 2006 Apr;81(4):271-80
pubmed: 16550521
Cancer Res. 1993 Jul 1;53(13):3092-7
pubmed: 8319216
J Urol. 2012 Jul;188(1):33-8
pubmed: 22578731
Cancer Res. 1991 Feb 15;51(4):1071-7
pubmed: 1671754
J Hematol Oncol. 2019 Sep 5;12(1):92
pubmed: 31488176
Trends Genet. 2003 Aug;19(8):432-8
pubmed: 12902161
Cancer. 1997 Sep 1;80(5):1004-5; author reply 1006-7
pubmed: 9307210
J Urol. 1998 Mar;159(3):714-7
pubmed: 9474132
Cancer. 1996 Dec 1;78(11):2421-6
pubmed: 8941014
Case Rep Oncol Med. 2013;2013:459282
pubmed: 24288636
Med Oncol. 2012 Dec;29(5):3335-8
pubmed: 22843308
Oncology. 1998 Sep-Oct;55(5):482-6
pubmed: 9732229
Curr Cancer Drug Targets. 2015;15(6):452-62
pubmed: 26282545
Cancer. 1991 Apr 1;67(7):2002-9
pubmed: 2004317
N Engl J Med. 1991 Jun 27;324(26):1893-4
pubmed: 2041555
Rambam Maimonides Med J. 2014 Oct 29;5(4):e0038
pubmed: 25386354
World J Nephrol Urol. 2015 Jun;4(2):213-217
pubmed: 27087881
J Natl Cancer Inst. 1993 Dec 1;85(23):1932-7
pubmed: 8230284
Med Oncol. 2010 Mar;27(1):55-8
pubmed: 19212710
BJU Int. 2008 Mar;101(6):712-5
pubmed: 17970789
Cancer. 1996 Jun 1;77(11):2325-31
pubmed: 8635103
Fam Cancer. 2016 Oct;15(4):677-87
pubmed: 27334456